@CombatCancer #HIVEC#HIPEC Combat team looking forward to upcoming BAUN exhibition @BAUNnurses
#hivec #hipec @CombatCancer Combat proud to be selected to be part of the medtech and pharma Parliamentary Review here we are at Westminster
Bom dia! Another successful PRS+ CO2 Agitation HIPEC Case in Portugal - parabens! @CombatCancer @ESSOnews @SPeritoneum #HIPEC #CombatCancer
@AndreasBrandl8 @FarazKh65499316 @APcolkins @BasingstokePmi @SPeritoneum @ESSOnews Glückwunsch Andreas!
Dr Francesco Chiancone @francescok86 presenting at @SIU_Italia on their great results with #HIVEC #SIU19
https://t.co/1IvWodPemg
Dr Francesco Chiancone @francescok86 presenting at @SIU_Italia on their great results with #HIVEC #SIU19
https://t.co/1IvWodPemg
Poster Presented at ESSO2019 in Rotterdam by Surgeons from Hospital Principe de Asturias, Alcala, Spain show HIPEC + CO2 Agitation is a "safe technique with superior survival results" in this series of patients #HIPEC #HIVEC @CombatCancer
#HIPEC Posters presented at 39th ESSO Meeting 2019 by Surgeons from Hospital Principe de Asturias (Alcala, Spain),
"HIPEC + CO2 Agitation a safe and efficient HIPEC technique"
Come and join us at stand nr.4 at the 39th ESSO 2019 in Rotterdam from October 9th-11th and learn more about PRS+ (CO2) Agitation HIPEC delivery @CombatCancer @ESSOnews @esso2019
Things are packed! To know more about PRS + CO2 Agitation - HIPEC
Visit us at booth Nr.4 during this years 39th ESSO in Rotterdam @CombatCancer @ESSOnews @GECOP_ @SPeritoneum @aecirujanos @PMPSurvivor @acpmpresearch #HIPEC #PRS #combatcancer
COMBAT is attending the EURO PMP International Workshop in Pseudomyxoma Peritoneí in Córdoba today - visit us at our stand @CombatCancer @HUReinaSofia @ESSOnews @GECOP_ @aecirujanos @SPeritoneum @alarjosan
PRS+ (CO2) Agitation-HIPEC case at the São João Hospital in Porto #hipec #prs #combatcancer #co2agitation #medicinalia-Cormédica @CombatCancer @ESSOnews @GECOP_ @SPeritoneum
Proud to be speaking again at the Masterclass in Uro-Oncology in Delhi, presenting our clinical results.
#BladderCancer #HIVEC #India
40 patients took part in the study, split into two groups – one which received the HIVEC™ treatment prior to a resection of the bladder, and another which received HIVEC after resection of the bladder.
97% of the patients were able to complete the full course of HIVEC treatments, and the majority of participants responded well to the treatment and show low rates of recurrence. Furthermore, the majority of the side-effects were low grade and had very little effect on the treatment plan.
Click Here to read the full article
Click Here to read the interview with the research author
